Equities

Guangzhou LBP Medicine Science & Technology Co Ltd

688393:SHH

Guangzhou LBP Medicine Science & Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)14.30
  • Today's Change-5.89 / -29.17%
  • Shares traded246.58k
  • 1 Year change-45.73%
  • Beta0.9270
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)495.46m
  • Net income in CNY32.09m
  • Incorporated2005
  • Employees907.00
  • Location
    Guangzhou LBP Medicine Science & Technology Co LtdNo. 2, Kexin Street, Fengxin RoadScience City, Huangpu DistrictGUANGZHOU 510663ChinaCHN
  • Phone+86 2 032210051
  • Fax+86 2 032290284
  • Websitehttp://www.gzlbp.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
688393:SHH since
announced
Transaction
value
Guangzhou LBP Medical Laboratory Co LtdAnnounced30 Aug 202430 Aug 2024Announced-5.74%631.00k
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Nanfang Medical Co Ltd584.85m-167.99m1.29bn858.00--2.83--2.21-0.5812-0.58122.021.580.42941.863.49681,641.10-12.31-1.09-28.91-2.005.6420.14-28.66-1.910.3748-9.580.5314--10.034.57-906.35---3.18--
Suzhou Iron Technology Co Ltd323.32m-43.37m1.30bn680.00--1.73--4.01-0.5716-0.57164.249.720.23431.931.18475,466.10-3.407.11-5.4810.5646.2456.00-14.5219.171.23-4.900.257125.00-23.848.73-71.17-10.4036.50--
CareRay Digital Medical Technology CoLtd287.84m24.70m1.32bn252.0054.181.55--4.590.27690.27693.229.690.30621.603.921,142,221.002.626.652.857.3742.7641.178.5515.646.76--0.022427.6133.815.17374.05-20.7477.38--
Touchstone International Medi Sci Co Ltd274.03m56.95m1.53bn243.0025.732.67--5.570.7310.7313.517.050.43523.1618.941,127,699.009.0510.0910.0610.8255.9657.5920.7820.174.76--0.002824.669.3116.349.5315.39-2.39--
Thalys Medical Technology Group Corp1.90bn-210.78m1.65bn1.41k--1.55--0.8715-1.36-1.3611.685.310.55084.161.221,349,051.00-6.04-0.8933-11.27-1.6218.5122.12-10.97-1.491.43-0.96660.4974---13.108.77-2.69---19.20--
Shanghai Rendu Biotechnology Co Ltd177.96m21.27m1.67bn358.0078.731.81--9.410.53180.53184.4523.180.17341.292.41497,088.502.076.262.227.1779.8774.3611.9514.5412.02--0.00527.96-45.8918.85-64.60--23.48--
Guangzhou LBP Medicine Scnc&Tech Co Ltd495.46m32.09m1.89bn907.0059.141.48--3.810.34140.34145.2113.620.35942.011.98546,263.801.845.101.925.5566.9275.155.1212.977.74--0.010124.42-1.9910.18-6.18-8.21-2.98--
Guangzhou Jet Bio-Filtration Co Ltd524.26m70.98m2.04bn1.09k25.921.74--3.880.55980.55984.138.320.32463.304.08480,536.104.419.354.6810.3937.7136.7613.6017.897.825.330.233329.64-24.0617.42-60.34-8.0247.32--
Allgens Medical Technology Co Ltd191.19m5.11m2.28bn202.00483.351.61--11.940.03480.03481.4510.490.12511.322.81946,490.300.02327.620.02418.3073.8783.600.185539.0524.27--0.03335.25-7.6812.86-43.0410.46-26.12--
Jiangsu Cowin Biotech Co Ltd118.17m-144.51m2.47bn657.00--1.61--20.94-1.30-1.301.0613.630.06671.321.43179,863.40-8.45---8.93--53.54---126.60--13.60--0.0214---67.15---153.00------
Data as of Sep 13 2024. Currency figures normalised to Guangzhou LBP Medicine Science & Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.72%Per cent of shares held by top holders
HolderShares% Held
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024546.82k2.58%
China Asset Management Co., Ltd.as of 30 Jun 2024270.74k1.28%
Mercer Global Investments Europe Ltd.as of 31 Dec 202389.45k0.42%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 202486.20k0.41%
Gfund Management Co., Ltd.as of 30 Jun 202464.38k0.30%
E Fund Management Co., Ltd.as of 30 Jun 202443.25k0.20%
Springs Fund Management Co. Ltd.as of 30 Jun 202434.20k0.16%
China Southern Asset Management Co., Ltd.as of 30 Jun 202430.53k0.14%
Western Leadbank Fund Management Co., Ltdas of 30 Jun 202424.40k0.12%
Broad Fund Management Co. Ltd.as of 30 Jun 202422.44k0.11%
More ▼
Data from 28 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.